

FORBIUS

Forbius Announces AVID200, a First-in-Class TGF-beta 1 & 3 Selective Inhibitor, to be Featured at ESMO and CICON 2019

- Presentations at CICON on Friday, Sep. 27, at 1:00 PM and 6:30 PM CEST and at ESMO on Saturday, Sep. 28, at 12:00 PM CEST
- AVID200 is a first-in-class, rationally designed inhibitor of TGF-beta 1 & 3, the main oncogenic TGF-beta isoforms
- AVID200 is undergoing Phase 1 testing in solid tumors and fibrosis

Austin, TX, and Montreal, QC (Sep. 23, 2019) – Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, announces presentations highlighting AVID200's immuno-oncology mode of action at the [Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference \(CICON\)](#) in Paris (Sep. 25 – 28) and [European Society of Medical Oncology \(ESMO\) 2019 Annual Congress](#) in Barcelona (Sep. 27 – Oct. 1).

The presentations describe the selective targeting of TGF-beta by AVID200 to increase T-cell-mediated cytotoxicity and immune cell infiltration, resulting in enhanced efficacy of immune checkpoint inhibitors when combined with AVID200 in syngeneic mouse tumor models.

Details of the Presentations Are as Follows:

CICON

Date: Friday, Sep. 27, 2019

Time: 1:00 – 3:00 PM and 6:30 – 8:00 PM CEST (Poster Session B)

Abstract #B041

The full abstract will be available online on Sep. 25

ESMO

Date: Saturday, Sep. 28, 2019

Time: 12:00 – 1:00 PM CEST

Location: Hall 4

Abstract #3582, Presentation Number 504P

[Link to online Program here](#) (search for AVID200 to see full abstract)

About Forbius: Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer

Forbius is a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer. We are focused on the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways.

Forbius' team of TGF-beta biology experts have designed a proprietary platform of TGF-beta inhibitors with best-in-class potency and selectivity against the principal disease-driving isoforms 1

FORBIUS

& 3. This novel class of TGF-beta inhibitors has proven highly active in preclinical models of fibrosis and cancer and was well-tolerated in long-term toxicology studies. Forbius' lead TGF-beta 1 & 3 inhibitor, AVID200, is undergoing Phase 1 clinical trials in two fibrotic indications as well as in solid tumors.

Forbius' lead program targeting EGFR is AVID100. AVID100 is an anti-EGFR antibody-drug conjugate (ADC) with a novel tumor-selective mode of action. This program is undergoing Phase 2a clinical trials in EGFR-overexpressing solid tumors.

About TGF-beta 1 & 3

TGF-beta 1 & 3 are the main oncogenic TGF-beta isoforms expressed by many solid tumors. They are believed to play a major role in T-cell suppression, fibrosis, and resistance to anti-PD-(L)1 therapies such as nivolumab (Opdivo®) and pembrolizumab (Keytruda®) ([Chakravarthy et al., Nature Comm., 2018](#); [Tauriello et al., Nature, 2018](#); [Mariathasan et al., Nature, 2018](#)).